(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex ® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results